Hoth Therapeutics rises as AI used to speed rare cancer drug development

Rocket One

04/03/2026 13:47

** Shares of Hoth Therapeutics HOTH.O rise 4.33% to $1.04 premarket

** Co says it is using OpenAI tools to help develop drug for rare cancers caused by faulty KIT gene, which can drive tumor growth

** Co says early tests of its experimental drug, HT-KIT, sharply lowered KIT gene levels in lab and animal studies, with no serious side effects

**  HOTH's HT-KIT also led to tumor shrinkage in animals within just over a week, co says

**  Co preparing to seek U.S. approval to begin human testing; drug has orphan status

** Shares up ~32% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))